EMD Serono, Inc. and FAST FORWARD, LLC Announce Recipients of Funding for Multiple Sclerosis Research
• EMD Serono and Fast Forward provide funding of over $1 million to accelerate early stage research in MS
Rockland, MA/New York, NY, 30 JUNE, 2011 – EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, and Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society, today announced the second group of recipients to receive funding through their collaboration, which is designed to speed research advances in mutually selected, high potential areas of MS research.
The awards total over $1million and will be distributed from two funds created by EMD Serono and Fast Forward to encourage early stage drug discovery for MS: the Accelerating Commercial Development Fund which is allocated to development programs for for-profit entities and the Accelerating Innovation Fund which is allocated to innovation projects and available to university-based investigators and seed-stage for-profit entities.
EMD Serono and Fast Forward distributed a call for proposals to fund projects focused on central nervous system neuroprotection and/or repair strategies. These priority areas were determined by a joint steering committee comprising Fast Forward staff and representatives from EMD Serono and Merck KGaA.